6-benzyl-3-(2-chloro-phenyl)-[1,2,4]triazolo[4,3-a]pyridine | 745826-93-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 6-benzyl-3-(2-chloro-phenyl)-[1,2,4]triazolo[4,3-a]pyridine
• 英文别名: 6-Benzyl-3-(2-chlorophenyl)-[1,2,4]triazolo[4,3-a]pyridine
• CAS: 745826-93-1
• 化学式: C₁₉H₁₄ClN₃
• 分子量: 319.793
• InChiKey: JYFXJOSQMZQWCI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  30.2
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  6-Bromo-3-(2-chlorophenyl)[1,2,4]triazolo[4,3-a]pyridine 、 溴甲苯 在 四(三苯基膦)钯 锌 、 三甲基氯硅烷 作用下， 以 四氢呋喃 、 1,1-二溴乙烷 为溶剂， 反应 1.05h， 以7%的产率得到6-benzyl-3-(2-chloro-phenyl)-[1,2,4]triazolo[4,3-a]pyridine
  参考文献：
  名称：

  [EN] TRIAZOLO-PYRIDINES AS ANTI-INFLAMMATORY COMPOUNDS
  [FR] TRIAZOLO-PYRIDINES UTILISEES COMME COMPOSES ANTI-INFLAMMATOIRES

  摘要：

  本发明涉及具有以下式(I)的新型三唑吡啶，其中X为>CH2，>NH，硫，>S=O，>SO2或氧；其中所述的>CH2和>NH可以选择性地被适当的取代基取代；R1选自氢，(C1-C6)烷基和其他适当的取代基组成的群；R2选自氢，(Cl-C6)烷基和其他适当的取代基组成的群；s为0-4的整数；R3为R4，R5-(NR6)-，R5-S-，R5-(S=O)-，R5-(SO2)-，R5-SO2-NR6-，R5-(NR6)-SO2-，R5-O-，R5-(C=O)-，R5-(NR6)-(C=O)-，R5-(C=O)-NR6-，R5-O-(C=O)-，R5-(C=O)-O-，R5-CR7=CR8-或R5-C=-C-；使得R3的分子量小于500 AMU，最好小于250 AMU；R4，R5和R6分别选自氢，(C1-C6)烷基和其他适当的取代基组成的群；或其药学上可接受的盐；用于它们的制备的中间体，含有它们的药物组合物以及它们的药用。本发明的化合物是MAP激酶的有效抑制剂。它们在治疗炎症、骨关节炎、类风湿关节炎、癌症、中风或心脏病发作中的再灌注或缺血、自身免疫疾病和其他疾病中具有用途。

  公开号：

  WO2004072072A1

文献信息

• Novel triazolo-pyridines as anti-inflammatory compounds
  申请人：Braganza Frederick John

  公开号：US20050075365A1

  公开（公告）日：2005-04-07

  The present invention relates to novel triazolo-pyridines of the formula wherein X is >CH 2 , >NH, sulfur, >S═O, >SO 2 or oxygen; wherein said >CH 2 and >NH may optionally be substituted with a suitable substituent; R 1 is selected from the group consisting of hydrogen, (C 1 -C 6 )alkyl and other suitable substituents; R 2 is selected from the group consisting of hydrogen, (C 1 -C 6 )alkyl and other suitable substituents; s is an integer from 0-4; R 3 is R 4 , R 5 —(NR 6 )—, R 5 —S—, R 5 —(S═O)—, R 5 —(SO 2 )—, R 5 —SO 2 —NR 6 —, R 5 —(NR 6 )—SO 2 —, R 5 —O—, R 5 —(C═O)—, R 5 —(NR 6 )—(C═O)—, R 5 —(C═O)—NR 6 —, R 5 —O—(C═O)—, R 5 —(C═O)—O—, R 5 —CR 7 ═CR 8 — or R 5 —C≡C_; such that the molecular weight of R 3 is less than 500 AMU, preferably less than 250 AMU; R 4 , R 5 and R 6 are each selected from the group consisting of hydrogen, (C 1 -C 6 )alkyl and other suitable substituents; or a pharmaceutically acceptable salt thereof; to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use. The compounds of the present invention are potent inhibitors of MAP kinases. They are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.

  本发明涉及一种新型的三唑吡啶，其化学式为其中X为> CH2，> NH，硫，> S = O，> SO2或氧，其中所述的> CH2和> NH可以选择性地用适当的取代基进行取代；R1选自氢，（C1-C6）烷基和其他适当的取代基组成的群；R2选自氢，（C1-C6）烷基和其他适当的取代基组成的群；s为0-4的整数；R3为R4，R5-（NR6）-，R5-S-，R5-（S = O）-，R5-（SO2）-，R5-SO2-NR6-，R5-（NR6）-SO2-，R5-O-，R5-（C = O）-，R5-（NR6）-（C = O）-，R5-（C = O）-NR6-，R5-O-（C = O）-，R5-（C = O）-O-，R5-CR7 = CR8-或R5-C≡C_；使得R3的分子量小于500 AMU，最好小于250 AMU；R4，R5和R6分别选自氢，（C1-C6）烷基和其他适当的取代基；或其药学上可接受的盐；以及制备它们的中间体，含有它们的药物组合物和它们的医药用途。本发明的化合物是MAP激酶的有效抑制剂。它们用于治疗炎症，骨关节炎，类风湿性关节炎，癌症，脑卒中或心脏病的再灌注或缺血，自身免疫性疾病和其他疾病。
• Triazolo-pyridines as anti-inflammatory compounds
  申请人：Pfizer Inc.

  公开号：US07321040B2

  公开（公告）日：2008-01-22

  The present invention relates to novel triazolo-pyridines of the formula wherein X is >CH2, >NH, sulfur, >S═O, >SO2 or oxygen; wherein said >CH2 and >NH may optionally be substituted with a suitable substituent; R1 is selected from the group consisting of hydrogen, (C1-C6)alkyl and other suitable substituents; R2 is selected from the group consisting of hydrogen, (C1-C6)alkyl and other suitable substituents; s is an integer from 0-4; R3 is R4, R5—(NR6)—, R5—S—, R5—(S═O)—, R5—(SO2)—, R5—SO2—NR6—, R5—(NR6)—SO2—, R5—O—, R5—(C═O)—, R5—(NR6)—(C═O)—, R5—(C═O)—NR6—, R5—O—(C═O)—, R5—(C═O)—O—, R5—CR7═CR8— or R5—C≡C—; such that the molecular weight of R3 is less than 500 AMU, preferably less than 250 AMU; R4, R5 and R6 are each selected from the group consisting of hydrogen, (C1-C6)alkyl and other suitable substituents; or a pharmaceutically acceptable salt thereof; to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use. The compounds of the present invention are potent inhibitors of MAP kinases. They are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.

  本发明涉及新型三唑并吡啶的公式，其中X为>CH2、>NH、硫、>S═O、>SO2或氧；其中所述的>CH2和>NH可以选择性地用适当的取代基取代；R1选自氢、(C1-C6)烷基和其他适当的取代基组成的群；R2选自氢、(C1-C6)烷基和其他适当的取代基组成的群；s为0-4的整数；R3为R4、R5—(NR6)—、R5—S—、R5—(S═O)—、R5—(SO2)—、R5—SO2—NR6—、R5—(NR6)—SO2—、R5—O—、R5—(C═O)—、R5—(NR6)—(C═O)—、R5—(C═O)—NR6—、R5—O—(C═O)—、R5—(C═O)—O—、R5—CR7═CR8—或R5—C≡C—；其中R3的分子量小于500 AMU，优选小于250 AMU；R4、R5和R6各自选自氢、(C1-C6)烷基和其他适当的取代基；或其药学上可接受的盐；以及制备它们的中间体、含有它们的制药组合物和它们的药用用途。本发明的化合物是MAP激酶的强力抑制剂。它们在治疗炎症、骨关节炎、类风湿性关节炎、癌症、中风或心脏病的再灌注或缺血、自身免疫性疾病和其他疾病中有用。
• TRIAZOLO-PYRIDINES AS ANTI-INFLAMMATORY COMPOUNDS
  申请人：Pfizer Products Inc.

  公开号：EP1601672B1

  公开（公告）日：2006-07-26
• US7321040B2
  申请人：——

  公开号：US7321040B2

  公开（公告）日：2008-01-22
• [EN] TRIAZOLO-PYRIDINES AS ANTI-INFLAMMATORY COMPOUNDS<br/>[FR] TRIAZOLO-PYRIDINES UTILISEES COMME COMPOSES ANTI-INFLAMMATOIRES
  申请人：PFIZER PROD INC

  公开号：WO2004072072A1

  公开（公告）日：2004-08-26

  The present invention relates to novel triazolo-pyridines of the formula (I) wherein X is >CH2, >NH, sulfur, >S=O, >S02 or oxygen; wherein said >CH2 and >NH may optionally be substituted with a suitable substituent; R1 is selected from the group consisting of hydrogen, (C1-C6)alkyl and other suitable substituents; R2 is selected from the group consisting of hydrogen, (Cl-C6)alkyl and other suitable 10 substituents; s is an integer from 0-4; R3 is R4, R5-(NR6)-, R5-S-, R5-(S=O)-, R5-(S02)-, R5-S02-NR6-, R5-(NR6)-S02-, R5-O-,R5-(C=O)-, R5-(NR6)-(C=O)-, R5-(C=O)-NR6-, R5-O-(C=O)-, R5-(C=O)-O-, R5-CR7=CR8- or R5-C=-C-; such that the molecular weight of R3 is less than 500 AMU, preferably less than 250 15 AMU; R4, R5 and R6 are each selected from the group consisting of hydrogen, (C1-C6)alkyl and other suitable substituents; or a pharmaceutically acceptable salt thereof; to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use. The compounds of the present invention are potent inhibitors of MAP kinases. They are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.

  本发明涉及具有以下式(I)的新型三唑吡啶，其中X为>CH2，>NH，硫，>S=O，>SO2或氧；其中所述的>CH2和>NH可以选择性地被适当的取代基取代；R1选自氢，(C1-C6)烷基和其他适当的取代基组成的群；R2选自氢，(Cl-C6)烷基和其他适当的取代基组成的群；s为0-4的整数；R3为R4，R5-(NR6)-，R5-S-，R5-(S=O)-，R5-(SO2)-，R5-SO2-NR6-，R5-(NR6)-SO2-，R5-O-，R5-(C=O)-，R5-(NR6)-(C=O)-，R5-(C=O)-NR6-，R5-O-(C=O)-，R5-(C=O)-O-，R5-CR7=CR8-或R5-C=-C-；使得R3的分子量小于500 AMU，最好小于250 AMU；R4，R5和R6分别选自氢，(C1-C6)烷基和其他适当的取代基组成的群；或其药学上可接受的盐；用于它们的制备的中间体，含有它们的药物组合物以及它们的药用。本发明的化合物是MAP激酶的有效抑制剂。它们在治疗炎症、骨关节炎、类风湿关节炎、癌症、中风或心脏病发作中的再灌注或缺血、自身免疫疾病和其他疾病中具有用途。